PharmaBoardroom

Christoph Stoller, the recently appointed president of Medicines for Europe, outlines the mission of his presidency, how the association and its…

Professor Jackie Hunter looks at why the pharmaceutical industry has been so slow to adopt artificial intelligence-based technologies and makes a…

The AAM’s Chip Davis tackles the issue of abandonment within US healthcare and proposes three measures to boost competition, thereby lowering drug…

Suchart Chookruvong and Wanna Thanesanont of Thai generics player Polipharm, highlight the growing importance of R&D within their strategy, how…

David H. Crean, managing director for Objective Capital Partners, highlights the latest trends in mergers and acquisition (M&A) activities…

Vishal Doshi looks at how AI is already revolutionising healthcare in Asia-Pacific and the work still to be done on the foundational elements –…

With Minister of the Economy and Finance, Bruno Le Maire, emphasizing the importance of “winning the battle on data” and eccentric mathematician…

France – one of the most influential countries in the development of gene therapy– still stands as a global powerhouse in the field, with…

Dr Kamala Maddali looks at how artificial intelligence is currently being utilized across the healthcare spectrum and why the time is now for Big…

Dr Li Shuai of pain- and CNS-focused Chinese biotech SIMR outlines the history of the company, the unmet medical needs it is seeking to address, its…

Mengchu Wu, CEO of Health Genetech, introduces the innovative precision medicine company as it prepares to transition from a research-positioned…

Founded in Sweden in 2005, and with operations in 13 European countries, Bluefish Pharmaceuticals has become one of the world’s most progressive…